UMHAT"Kaspela", EOOD Trials

UMHAT"Kaspela", EOOD	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Penev, Dimitar

SunStone, NCT06559163: A Study of Obexelimab in Patients with Systemic Lupus Erythematosus

Recruiting

190

Europe, Japan, US, RoW

Obexelimab, Placebo

Zenas BioPharma (USA), LLC

Systemic Lupus Erythematosus

06/26

09/26

Samsonov, Mikhail

RESET, NCT05187793: Study of Efficacy of Different Treatment Regimens of Olokizumab

Active, not recruiting

198

RoW

Olokizumab, Standard therapy

R-Pharm, Federal Budget Institution of Science "Central Research Institute of Epidemiology" of the Rospotrebnadzor, Group of companies Medsi, JSС

COVID-19

10/22

04/23

NCT06320353: Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma

Active, not recruiting

266

RoW

RPH-075, pembrolizumab, Arfleyda, Keytruda®

R-Pharm, Data Management 365, Exacte Labs LLC, Federal State Budgetary Institution of the Central Research Institute of Epidemiology of Rospotrebnadzor

Skin Melanoma

06/24

01/26

NCT05432960: Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)

Withdrawn

RoW

RPH-104, goflikicept, Arcerix, Placebo

R-Pharm International, LLC, Exacte Labs LLC, Federal State Budgetary Educational Institution for Higher Education FSPbSMU n. a. I.P. Pavlov of the Ministry of Health of the Russian Federation, Scientific Center EFiS LLC, Data Management 365

Adult-Onset Still's Disease, AOSD

08/25

NCT05673902: Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis

Active, not recruiting

RoW

RPH-104, goflikicept, Arcerix

R-Pharm International, LLC, R-Pharm, Unimed Laboratories CJSC, Data Management 365, Exacte Labs LLC

Idiopathic Recurrent Pericarditis

01/26

NCT06440746: Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases

Recruiting

2/3

116

RoW

Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL), Artlegia, SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL

R-Pharm International, LLC, R-Pharm, Exacte Labs LLC, Data Management 365, Keystat, LLC

Lung Diseases, Interstitial

06/26

12/26

NCT05092776: Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine

Active, not recruiting

RoW

RPH-104, Placebo

R-Pharm International, LLC, Data Management 365, Atlant Clinical LLC, R-Pharm JSC, Unimed Laboratories CJSC, Exacte Labs LLC, Key Stat LLC, TRPharm İlaç Sanayi Ticaret Anonim Şirketi and ASCOT SCIENCE Education and Consulting Ltd., Ascot Eğitim ve Danışmanlık LTD. ŞTİ.

Familial Mediterranean Fever, FMF

01/25

10/25

NCT05190991: Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

Recruiting

RoW

RPH-104

R-Pharm International, LLC, Atlant Clinical LLC, Unimed Laboratories CJSC, Data Management 365, R-Pharm JSC, TRPharm İlaç Sanayi Ticaret Anonim Şirketi and ASCOT SCIENCE Education and Consulting Ltd., Exacte Labs LLC, Key Stat LLC

Familial Mediterranean Fever, FMF

12/28

01/29

NCT06307093: Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms

Active, not recruiting

RoW

RPH-075, pembrolizumab, Keytruda®

R-Pharm, Data Management 365, Exacte Labs LLC, Federal State Budgetary Institution "NMIC of Hematology" of the Ministry of Health of the Russian Federation, Federal State Budgetary Institution of the Central Research Institute of Epidemiology of Rospotrebnadzor

Skin Melanoma, Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma

12/23

07/25

NCT05773170: Efficacy and Safety Evaluation of Refralon®, Concentrate for Solution for Intravenous Injection in Patients With Paroxysmal and Persistent Atrial Fibrillation and Flutter

Completed

N/A

1147

RoW

Refralon, 4-nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride, Niferidyl

R-Pharm, FSBI "National Medical Research Center of Cardiology named after academician E.I.Chazov" of the Ministry of Health of the Russian Federation

Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Atrial Flutter

06/23



	Diseases Companies Products Productz Mechanisms of Action Sites